



## Orgovyx™ (relugolix) – New drug approval

- On December 18, 2020, the [FDA announced](#) the approval of Myovant Sciences' [Orgovyx \(relugolix\)](#), for the treatment of adult patients with advanced prostate cancer.
- The American Cancer Society estimates that in 2020, there will have been more than 190,000 cases of prostate cancer in the U.S. Androgen deprivation therapy (eg, gonadotropin-releasing hormone [GnRH] receptor antagonists) is a commonly used treatment option for patients with advanced prostate cancer. Previously approved treatments of this type were injected or placed as small implants under the skin.
  - Orgovyx is the first oral GnRH receptor antagonist approved for prostate cancer.
- The efficacy of Orgovyx was established in the HERO trial, a randomized, open-label study in 934 men with advanced prostate cancer. Patients received Orgovyx orally once daily or leuprolide injection (eg, [Lupron Depot®](#)) subcutaneously every 3 months. The major efficacy outcome measure was medical castration rate defined as achieving and maintaining serum testosterone suppression to castrate levels (< 50 ng/dL) by day 29 through 48 weeks of treatment.
  - Medical castration was achieved in 96.7% (95% CI: 94.9, 97.9) of patients treated with Orgovyx vs. 88.8% (95% CI: 84.6, 91.8) with leuprolide.
- Warnings and precautions for Orgovyx include QT/QTc interval prolongation, embryo-fetal toxicity, and laboratory testing.
- The most common adverse reactions ( $\geq 10\%$ ) and laboratory abnormalities ( $\geq 15\%$ ) with Orgovyx use were hot flush, glucose increased, triglycerides increased, musculoskeletal pain, hemoglobin decreased, alanine aminotransferase (ALT) increased, fatigue, aspartate aminotransferase (AST) increased, constipation, and diarrhea.
- Treatment of Orgovyx should be initiated with a loading dose of 360 mg on the first day and treatment should be continued with a 120 mg dose taken orally once daily at approximately the same time each day.
  - If treatment with Orgovyx is interrupted for greater than 7 days, Orgovyx should be restarted with a loading dose of 360 mg on the first day and then continued with a dose of 120 mg once daily.
  - In patients treated with GnRH receptor agonists and antagonists for prostate cancer, treatment is usually continued upon development of nonmetastatic or metastatic castration-resistant prostate cancer.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.



- Myovant Sciences' launch plans for Orgovyx are pending. Orgovyx will be available as a 120 mg tablet.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.